Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23979376 | 0.92 | DDB1 (0.64) | CRBNDDB1MAPK1NPC1GAA | |
| SCHEMBL19586342 | 0.83 | CRBN (1.00) | CRBNDDB1MAPK1NPC1GAA | |
| SCHEMBL23979389 | 0.79 | DDB1 (0.51) | CRBNDDB1MAPK1GAAALDH1A1 | |
| SCHEMBL12041931 | 0.77 | DDB1 (0.58) | CRBNDDB1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL19936664 | 0.75 | DDB1 (0.62) | CRBNDDB1MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL2542693 | 0.75 | DDB1 (0.54) | CRBNDDB1MAPK1ALDH1A1LMNA | |
| SCHEMBL10611547 | 0.74 | DDB1 (0.62) | CRBNDDB1MAPK1NPC1GAA | |
| SCHEMBL27903423 | 0.74 | CRBN (0.43) | CRBNDDB1 | |
| SCHEMBL2361135 | 0.73 | DDB1 (0.77) | CRBNDDB1MAPK1NPC1GAA | |
| Hydrochloric Acid SCHEMBL2805409 | 0.73 | DDB1 (0.52) | CRBNDDB1MAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309436-A1 | THALIDOMIDE ANALOGS | P2D, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8853253-B2 | Thalidomide analogs | P2D, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8546430-B2 | Thalidomide analogs | P2D, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2438053-B1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2013-09-11 | — | — | EP | disclosed |
| US-20130035363-A1 | Thalidomide Analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2438053-A1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-04-11 | — | — | EP | disclosed |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | The Government of the United States of America, as represented by the Secretary of | 2011-10-06 | — | — | US | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| EP-1957481-B1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | GRUENENTHAL GMBH (DE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2010139266-A1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2010-12-09 | — | — | WO | disclosed |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | GRUENENTHAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| EP-1957481-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062817-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2007-06-07 | — | — | WO | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035363-A1 | Thalidomide Analogs | TNF, TNFRSF1A, TNFRSF9 | CRBN 241/4885DDB1 919/4885MAPK1 3233/4885 |
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | CRBN 321/4885DDB1 953/4885MAPK1 3942/4885 |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, TNFRSF9 | CRBN 241/4885DDB1 919/4885MAPK1 3233/4885 |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, PGF | CRBN 321/4885DDB1 953/4885MAPK1 3942/4885 |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | TPMT, MALT1, THPO | CRBN 1317/4885DDB1 1517/4885MAPK1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.